FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.24  |  FHIR Version n/a  User: [n/a]

1131411000001104: Cabergoline 4mg tablets 16 tablet (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-May 2006. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
21651701000001113 Cabergoline 4mg tablets 16 tablet (product) en Fully specified name Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module
21651801000001116 Cabergoline 4mg tablets 16 tablet en Synonym Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module

6 descendants. Search Descendants:

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Cabergoline 4mg tablets 16 tablet Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet Is a Virtual medicinal product pack true Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet Is pack of Product containing precisely cabergoline 4 milligram/1 each conventional release oral tablet false Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet Has active ingredient Cabergoline false Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet VMP non-availability indicator Available false Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet Has manufactured dose form Conventional release oral tablet false Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet Has VMP Product containing precisely cabergoline 4 milligram/1 each conventional release oral tablet true Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet Has specific active ingredient Cabergoline true Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets 16 tablet VMP non-availability indicator Not available true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Cabaser 4mg tablets (Pfizer Ltd) 16 tablet Is a True Cabergoline 4mg tablets 16 tablet Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets (Teva UK Ltd) 16 tablet Is a True Cabergoline 4mg tablets 16 tablet Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets (Unichem Plc) 16 tablet Is a True Cabergoline 4mg tablets 16 tablet Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets (A A H Pharmaceuticals Ltd) 16 tablet Is a True Cabergoline 4mg tablets 16 tablet Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets (Dowelhurst Ltd) 16 tablet Is a True Cabergoline 4mg tablets 16 tablet Inferred relationship Existential restriction modifier
Cabergoline 4mg tablets (Sigma Pharmaceuticals Plc) 16 tablet Is a True Cabergoline 4mg tablets 16 tablet Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start